...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: A direct and adjusted indirect comparison meta-analysis
【24h】

Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: A direct and adjusted indirect comparison meta-analysis

机译:可切除的胃和胃-食管连接癌的术前放化疗的生存获益和附加价值:直接和调整后的间接比较荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Several phase I/II studies of chemoradiotherapy for gastric cancer have reported promising results, but the significance of preoperative radiotherapy in addition to chemotherapy has not been proven. In this study, a systematic literature search was performed to capture survival and postoperative morbidity and mortality data in randomised clinical studies comparing preoperative (chemo)radiotherapy or chemotherapy versus surgery alone, or preoperative chemoradiotherapy versus chemotherapy for gastric and/or gastro-oesophageal junction (GOJ) cancer. Hazard ratios (HRs) for overall mortality were extracted from the original studies, individual patient data provided from the principal investigators of eligible studies or the earlier published meta-analysis. The incidences of postoperative morbidities and mortalities were also analysed. In total 18 studies were eligible and data were available from 14 of these. The meta-analysis on overall survival yielded HRs of 0.75 (95% CI 0.65-0.86, P < 0.001) for preoperative (chemo)radiotherapy and 0.83 (95% CI 0.67-1.01, P = 0.065) for preoperative chemotherapy when compared to surgery alone. Direct comparison between preoperative chemoradiotherapy and chemotherapy resulted in an HR of 0.71 (95% CI 0.45-1.12, P = 0.146). Combination of direct and adjusted indirect comparisons yielded an HR of 0.86 (95% CI 0.69-1.07, P = 0.171). No statistically significant differences were seen in the risk for postoperative morbidity or mortality between preoperative treatments and surgery alone, or preoperative (chemo)radiotherapy and chemotherapy. Preoperative (chemo)radiotherapy for gastric and GOJ cancer showed significant survival benefit over surgery alone. In comparisons between preoperative chemotherapy and (chemo)radiotherapy, there is a trend towards improved survival when adding radiotherapy, without increased postoperative morbidity or mortality. (C) 2014 Elsevier Ltd. All rights reserved.
机译:胃癌放化疗的几项I / II期研究已报告了令人鼓舞的结果,但除化学疗法外,术前放疗的重要性尚未得到证实。在这项研究中,我们进行了系统的文献检索,以收集随机临床研究中的生存率,术后发病率和死亡率数据,比较了术前(化学)放射疗法或化学疗法与单纯手术相比,或术前放化疗与化学疗法治疗胃和/或胃食管连接( GOJ)癌症。总体死亡率的危险比(HRs)摘自原始研究,合格研究的主要研究者提供的个体患者数据或早期发表的荟萃分析。还分析了术后发病和死亡的发生率。总共有18项研究符合条件,其中14项可获得数据。与手术相比,术前放化疗总生存率的荟萃分析得出的HRs为0.75(95%CI 0.65-0.86,P <0.001),术前化疗为0.83(95%CI 0.67-1.01,P = 0.065)单独。术前放化疗与化学疗法之间的直接比较导致HR为0.71(95%CI 0.45-1.12,P = 0.146)。直接比较和调整间接比较的组合得出的HR为0.86(95%CI 0.69-1.07,P = 0.171)。术前治疗和单独手术或术前(化学)放疗和化疗之间的术后发病或死亡风险无统计学意义差异。胃癌和GOJ癌的术前(化学)放射治疗比单纯手术具有明显的生存获益。在术前化学疗法和(化学)放射疗法之间的比较中,增加放射疗法的生存率有提高的趋势,而不会增加术后发病率或死亡率。 (C)2014 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号